Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages 663-670

  Amadori, Dino ^a   Aglietta, Massimo ^b   Alessi, Barbara ^c   Gianni, Lorenzo ^d   Ibrahim, Toni ^a   Farina, Gabriella ^e   Gaion, Fernando ^f   Bertoldo, Francesco ^g   Santini, Daniele ^h   Rondena, Roberta ⁱ   Bogani, Paola ⁱ   Ripamonti, Carla I ^j  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d Infermi Hospital   (Italy)

^e FATEBENEFRATELLI HOSPITAL   (Italy)

^f ULSS 15   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

ⁱ Italy   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; ITALY; JAW OSTEONECROSIS; KIDNEY DISEASE; LIMB PAIN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; ORTHOPEDIC SURGERY; PAIN; PARESTHESIA; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINAL CORD COMPRESSION; SPINE FRACTURE; UPPER ABDOMINAL PAIN; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84878366329     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70174-8     Document Type: Article

References (31)

1. Coleman RE Bisphosphonates: clinical experience. Oncologist 2004, 9:14-27.
2. Bussard KM, Gay CV, Mastro AM The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev 2008, 27:41-55.
3. Coleman RE Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
4. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082-1090.
5. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42:164-175.
6. Costa L, Major PP Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009, 6:163-174.
7. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
8. Zometa (zoledronic acid) injection (package insert) 2009, Novartis Pharmaceuticals Corporation, East Hanover, (accessed Jan 11, 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021223s018lbl.pdf.
9. Holen I, Coleman RE Bisphosphonates as treatment of bone metastases. Curr Pharm Des 2010, 16:1262-1271.
10. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377-387.
11. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
12. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
13. De la Haba J, Rodriguez-Lescure A, Baena JM, et al. Final analysis of dose-density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 630.
14. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008, 113:1438-1445.
15. Duck L, Delforge M, Doyen C, et al. Long term treatment with zoledronic acid (≥ 2 years) in patients with metastatic bone disease or multiple myeloma: 6-month results from the LOTUZ study. Proc Am Soc Clin Oncol 2009, 27(suppl). poster N20.
16. Henk H, Teitelbaum A, Kaura S Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid. Curr Med Res Opin 2012, 28:1119-1127.
17. Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 2012, 119:5374-5383.
18. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
19. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
20. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
21. Hortobagyi GN Moving into the future: treatment of bone metastases and beyond. Cancer Treat Rev 2005, 31:9-18.
22. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:243-254.
23. Genant HK, Wu CY, van Kuijk C, Nevitt MC Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8:1137-1148.
24. Caraceni A, Cherny N, Fainsinger R, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002, 23:239-255.
25. Andersen PK, Gill RD Cox's regression model for counting processes: a large sample study. Ann Stat 1982, 10:1100-1120.
26. Major PP, Cook R Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002, 25:S10-S18.
27. Rodriguez-Lescure A, de la Haba J, Baena JM, et al. Second interim analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients. ZARAS study. 12th St Gallen International Breast Cancer Conference; St Gallen, Switzerland; March 16-19, 2011. Abstr P323.
28. Scariano JK, Glew RH, Bou-Serhal CE, Clemens JD, Garry PJ, Baumgartner RN Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 1998, 23:471-477.
29. Grey A, Bolland MJ, Horne A, et al. Five years of anti-resorptive activity after a single dose of zoledronate-results from a randomized double-blind placebo-controlled trial. Bone 2012, 50:1389-1393.
30. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
31. Coleman RE, Wright J, Houston S, et al. Randomized trial of marker-directed versus standard schedule of zoledronic acid for bone metastases from breast cancer. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 511.